List today: 89bio, Inc. ETNB is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days. Altice USA ...

Check the time stamp on this data. Updated AI-Generated Signals for 89bio Inc. (ETNB) available here: ETNB. Type a few ...

While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price dropped 3.7% during trading on Tuesday . The company traded as low as $7.50 and last traded at $7.50. Approximately 101,562 shares were traded during ...

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

89bio, Inc. SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development ...

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...